Literature DB >> 27519795

Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells.

Yi-Chia Lin1, Ji-Fan Lin2, Te-Fu Tsai1, Kuang-Yu Chou1, Hung-En Chen3, Thomas I-Sheng Hwang4.   

Abstract

BACKGROUND: Prostate cancer (PCa) is a leading cause of cancer-related death in men, which emphasizes the need for novel therapeutic approaches. Targeting microRNA (miRNA) has been considered as a therapeutic strategy against cancers. Human miR-204-5p potentially targeting BCL2 has been reported to be downregulated in various cancers. We hypothesized that miR-204-5p overexpression induces cancer cell apoptosis by repressing BCL2 expression.
METHODS: A vector harboring mature miR-204-5p was constructed and delivered into human PCa cells. The expression level of miR-204-5p was determined by miRNA quantitative polymerase chain reaction (QPCR). Luciferase reporter assays were performed to verify the function of mature miR-204-5p and its direct binding to BCL2 transcripts. The expression levels of BCL-2 messenger RNA (mRNA) and protein samples were measured by QPCR and Western blot, respectively. Cell viability was detected by WST-1 assays. Induction of apoptosis was determined by increased levels of cleavage caspase 3 and caspase 3/7 activity.
RESULTS: The expression levels of miR-204-5p were downregulated in PCa cells compared with normal prostate epithelial cells. Transfection of pSM-204 resulted in up to 6.2-fold higher expression of miR-204-5p when compared with pSM control. The mRNA levels of several potential target genes of miR-204-5p were decreased in pSM-204-transfected PC3 and Rv1 cells. BCL2 mRNA and protein expression decreased in miR-204-5p-transfected cells, which led to cytochrome C release from mitochondria. It subsequently increased cleaved caspase 3 and caspase 3/7 activities and reduced cell viability. Cotransfection of a reporter vector harboring the BCL2 3'-untranslated region to compete with endogenous transcripts partially rescued miR-204-5p-induced apoptosis.
CONCLUSION: Human miR-204-5p targets BCL2 in PCa cells. Restoration of miR-204-5p in PCa could therefore be considered as a novel strategy by targeting antiapoptotic BCL2.
Copyright © 2016. Published by Elsevier Taiwan.

Entities:  

Keywords:  BCL2; apoptosis; microRNAs; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27519795     DOI: 10.1016/j.asjsur.2016.07.001

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  26 in total

Review 1.  Targeting IGF1R pathway in cancer with microRNAs: How close are we?

Authors:  Arathy S Kumar; Suresh K Rayala; Ganesh Venkatraman
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

2.  [Effect of miR-204-5p on the proliferation, migration, and invasion on tongue squamous cell carcinoma SCC25 cells by targeting bromodomain-containing protein 4].

Authors:  Jing Zheng; Yu-Wen Zhang; Tian-Ke Li; Yang Bao; Su-Xin Zhang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-04-01

3.  microRNA-204 modulates chemosensitivity and apoptosis of prostate cancer cells by targeting zinc-finger E-box-binding homeobox 1 (ZEB1).

Authors:  Guanlin Wu; Jian Wang; Guojun Chen; Xing Zhao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating β-catenin and causing activation of FOXO3a.

Authors:  Ming Lu; Yong Wang; Shizhen Zhou; Jun Xu; Jing Li; Rongjie Tao; Yufang Zhu
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

Review 5.  Oncogenic and Tumor-Suppressive Roles of MicroRNAs with Special Reference to Apoptosis: Molecular Mechanisms and Therapeutic Potential.

Authors:  Dharambir Kashyap; Hardeep Singh Tuli; Vivek Kumar Garg; Neelam Goel; Anupam Bishayee
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

6.  Association of Some Polymorphisms in the VDR Gene, CYP17 Gene and SRD5A2 Gene and Prostate Cancer among Lebanesezzm321990Men

Authors:  Asmahan A El Ezzi; Vladyslav G Boyko; Monika T Baker; Wissam R Zaidan; Kalim M Hraiki; Mohammad A El Saidi; Ruhul H Kuddus
Journal:  Asian Pac J Cancer Prev       Date:  2017-01-01

Review 7.  Micrornas in prostate cancer: an overview.

Authors:  Daniela Vanacore; Mariarosaria Boccellino; Sabrina Rossetti; Carla Cavaliere; Carmine D'Aniello; Rossella Di Franco; Francesco Jacopo Romano; Micaela Montanari; Elvira La Mantia; Raffaele Piscitelli; Flavia Nocerino; Francesca Cappuccio; Giovanni Grimaldi; Alessandro Izzo; Luigi Castaldo; Maria Filomena Pepe; Maria Gabriella Malzone; Gelsomina Iovane; Gianluca Ametrano; Paola Stiuso; Lucio Quagliuolo; Daniela Barberio; Sisto Perdonà; Paolo Muto; Maurizio Montella; Piera Maiolino; Bianca Maria Veneziani; Gerardo Botti; Michele Caraglia; Gaetano Facchini
Journal:  Oncotarget       Date:  2017-07-25

8.  miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanoma.

Authors:  Wenkang Luan; Yao Qian; Xin Ni; Xuefeng Bu; Yun Xia; Jinlong Wang; Hongru Ruan; Shaojun Ma; Bin Xu
Journal:  Onco Targets Ther       Date:  2017-02-27       Impact factor: 4.147

9.  Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia.

Authors:  Aleksandra Butrym; Piotr Łacina; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik; Grzegorz Mazur
Journal:  BMC Cancer       Date:  2018-01-30       Impact factor: 4.430

Review 10.  Targeting MicroRNAs in Prostate Cancer Radiotherapy.

Authors:  Jie Ni; Joseph Bucci; Lei Chang; David Malouf; Peter Graham; Yong Li
Journal:  Theranostics       Date:  2017-07-23       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.